Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.

[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.

[3] On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.

This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.